Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

XL147

Known as: PI3K Family Kinase Inhibitor XL147 
An orally bioavailable small molecule, targeting the class I phosphatidylinositol 3 kinase (PI3K) family of lipid kinases, with potential… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
OBJECTIVE Patients with endometrial carcinoma who progress after first-line chemotherapy have a poor prognosis. Phosphoinositide… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Dysregulation of PI3K/PTEN pathway components, resulting in hyperactivated PI3K signaling, is frequently observed in various… Expand
  • table 1
  • table 2
  • table 3
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Deregulation of phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Purpose: SAR245408 is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. This phase I study determined the maximum… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The antibody trastuzumab is approved for treatment of patients with HER2 (ERBB2)-overexpressing breast cancer. A significant… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
  • K. Polyak, P. Vogt
  • Proceedings of the National Academy of Sciences
  • 2012
  • Corpus ID: 26665840
Breast cancer is a heterogeneous disease composed of multiple different subtypes with distinct molecular features and clinical… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
We examined the effects of an inhibitor of PI3K, XL147, against human breast cancer cell lines with constitutive PI3K activation… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2010
Highly Cited
2010
3004 Background: XL147 is a selective inhibitor of class I PI3K isoforms. In preclinical cancer models, XL147 is cytostatic or… Expand
Is this relevant?
2010
2010
3078 Background: Upregulation of PI3K pathway signaling is associated with tumor resistance to P and C. The oral selective Class… Expand
Is this relevant?
2009
2009
3500 Background: XL147 is a selective inhibitor of Class I PI3K isoforms. In preclinical cancer models XL147 is cytostatic or… Expand
Is this relevant?